**Core tip:** We investigated the effects and the underlying mechanism of action of *Polygonatum kingianum* (*P. kingianum*) on high-fat diet (HFD)-induced dyslipidemia in rats using an integrated untargeted metabolomic method. The results indicated that *P. kingianum* alleviated HFD-induced dyslipidemia by regulating a large number of endogenous metabolites in serum, urine and liver. This involved phenylalanine, tyrosine, tryptophan, valine, leucine and isoleucine biosynthesis, and tryptophan, tyrosine, phenylalanine, starch, sucrose, glycerophospholipid, arachidonic acid, linoleic acid, nicotinate, nicotinamide and sphingolipid metabolism. *P. kingianum* may be a promising lipid regulator to remedy dyslipidemia and further alleviate its related diseases.

INTRODUCTION
============

Dyslipidemia is a core characteristic of the metabolic syndrome, and is an important risk factor for atherosclerosis, coronary heart disease, stroke and other cardiovascular and cerebrovascular diseases. It is also closely related to many significant diseases such as diabetes and nephropathy\[[@B1]\]. Dyslipidemia is divided into two types, referred to as primary and secondary dyslipidemia. Primary dyslipidemia has a genetic history and may be caused by congenital enzyme defects. Secondary dyslipidemia is usually present in patients with diseases such as diabetes mellitus, hypothyroidism, nephrotic syndrome, biliary obstruction, pancreatitis, gout, alcoholism, and various liver disorders\[[@B2]\]. The improvement in living standards and associated lifestyle changes have led to dyslipidemia being considered one of the most important risk factors for metabolic diseases worldwide\[[@B3]\]. Therefore, management of dyslipidemia is of vital importance to prevent and cure a variety of acute and chronic human diseases.

The commonly used lipid regulators include statins, fibrates, nicotinic acid and variants, bile acid sequestrants and inhibitors of cholesterol absorption. These drugs can be effective for treating dyslipidemia, but have significant adverse effect profiles\[[@B4]\]. For example, statins may increase blood glucose concentrations, cause rhabdomyolysis or damage the liver and kidneys\[[@B5]\]. Traditional Chinese medicines (TCMs) are one of the world's oldest herbal medicines and have been applied extensively by TCM practitioners for thousands of years\[[@B6]\]. TCMs have an indispensable role in the prevention and treatment of human diseases, especially those that are complicated and chronic\[[@B7]\]. As a complementary therapy technique with fewer side effects than Western medicines, TCMs have been employed widely to regulate lipid metabolic disorders\[[@B8]\]. Thus, TCMs may serve as the basis for development of new lipid-regulating drugs or health products.

*Rhizoma polygonati*, first recorded in *Mingyi Bielu* in 220-450 AD (written by Hong-Jing Tao), has been used as a TCM and nutritional food for over 2000 years. *Polygonatum kingianum* Coll. et Hemsl., *Polygonatum sibiricum* Red. and *Polygonatum cyrtonema* Hua are described in the Chinese Pharmacopoeia (2015 edition) as legal sources of *Rhizoma polygonati*. *Polygonatum kingianum* (*P. kingianum*; Figure [1](#F1){ref-type="fig"}) is mainly distributed in the Chinese provinces of Yunnan, Sichuan, Guizhou and Guangxi. It is mainly comprised of saponins and polysaccharides, and has pharmacological activities that include immune system stimulation, anti-aging effects and blood glucose regulation\[[@B9],[@B10]\]. Our previous research showed that the total saponins and total polysaccharides from *P. kingianum* had blood glucose and lipid regulating activities\[[@B11],[@B12]\]. However, the lipid-regulating effects of *P. kingianum* and the mechanism for these remain unclear.

![*Polygonatum kingianum*. A: Whole plant photograph of *Polygonatum kingianum (P. kingianum)*; B: Rhizome of *P. kingianum*, which represents the medicinal part of this plant used in this study.](WJG-24-5505-g001){#F1}

Metabolomics can comprehensively characterize small molecule metabolites in biological systems. It can also provide an overview of metabolic status and global biochemical events after external stimulation such as in disease models and after drug treatment\[[@B13]\]. Metabolomics is a novel method in pharmacological and pharmacodynamic studies that is increasingly employed to assess the therapeutic and toxic effects of herbal TCMs and TCM prescriptions, and their mechanism of action\[[@B14]\].

In the present study, we investigated the lipid-regulating effects and the underlying mechanism of action of *P. kingianum* on high-fat diet (HFD)-induced dyslipidemia in rats. An integrated untargeted metabolomic method was used, which was based on ultra-high performance liquid chromatography/mass spectrometry (UHPLC/MS) analysis of serum, urine and liver samples (Figure [2](#F2){ref-type="fig"}). The results indicated that *P. kingianum* alleviated HFD-induced dyslipidemia by regulating many endogenous metabolites in serum, urine and liver samples. Taken together, these findings indicated that *P. kingianum* may be a promising lipid regulator to treat dyslipidemia and further alleviate associated diseases.

![Workflow of the integrated untargeted metabolomic method based on ultra-high performance liquid chromatography/mass spectrometry analysis of serum, urine and liver samples. UHPLC/MS: Ultra-high performance liquid chromatography/mass spectrometry.](WJG-24-5505-g002){#F2}

MATERIALS AND METHODS
=====================

Chemicals, reagents and materials
---------------------------------

Kits for quantifying triglyceride (TG) and total cholesterol (TC) concentrations were purchased from ZhongshengBei Biotech Co., Ltd. (Beijng, China). Bicinchoninic Acid (BCA) Protein Determination Kit was obtained from Beyotime Institute of Biotechnology (Shanghai, China). Simvastatin was purchased from Hangzhou Merck East Pharmaceutical Co., Ltd. (Hangzhou, China). HPLC-grade formic acid and acetonitrile were acquired from Merck (Darmstadt, Germany). Basal rodent diet (calories provided from carbohydrates, proteins and fat were 62%, 26% and 12%, respectively) was obtained from Suzhou Shuangshi Experimental Animal Feed Technology Co., Ltd. (Suzhou, China). Cholesterol, refined lard, and eggs were supplied by Beijing Boao Extension Co., Ltd. (Beijing, China), Sichuan Green Island Co., Ltd. (Chengdu, China) and Wal-Mart Supermarket (Kunming, China), respectively. High-purity deionized water was purified using a Milli-Q system (Millipore, Bedford, MA, United States). All other reagents were of analytical grade or higher. The rhizome of *P. kingianum* was purchased from Wenshan Shengnong Trueborn Medicinal Materials Cultivation Cooperation Society (Wenshan, China) on 07 April 2017. Samples were authenticated by Professor Jie Yu and a voucher specimen (No. 8426) was deposited in the Key Laboratory of Preventing Metabolic Diseases of Traditional Chinese Medicine, Yunnan University of Traditional Chinese Medicine (Kunming, China).

Preparation of P. kingianum extract
-----------------------------------

*P. kingianum* rhizome was processed according to regulations in the Chinese Pharmacopoeia (2015 edition). Briefly, fresh *P. kingianum* rhizome was separated from fibrous roots, washed, cut into thick slices and dried at 50 °C. The dried materials were then infiltrated in a 5-fold volume of Shaoxing rice wine (Beijing Ershang Wangzhihe Food Co., Ltd., Beijing, China), and then placed in a steam sterilizer (LDZX-50 KBS, Shanghai Shenan Medical Instrument Factory, Shanghai, China) at 120 °C for 2.5 h. After cooling for 3 h, the steamed materials were dried at 60 °C.

The steamed and dried *P. kingianum* sample was pulverized, immersed in a 7-fold volume of water for 30 min and then decocted with water for 60 min. The filtrates were collected after leaching. The dregs were decocted successively with a 7-fold volume of water for a further 60 min, and the extracted liquids filtered. The two filtrates were then combined and condensed using an R-210 rotatory evaporator (Büchi Labortechnik AG, Flawil, Switzerland) under reduced pressure at 50 °C. Finally, the concentrates were lyophilized to a powder using a FD5-3 freeze dryer (SIM International Group Co. Ltd., Newark, DE, United States). The obtained sample powder was stored in a desiccator at room temperature until use.

Animal experiments
------------------

Healthy male Sprague-Dawley rats (200 ± 50 g) were obtained from Dashuo Biotech. Co., Ltd. (Chengdu, China). They were adjusted to a controlled environment (22 ± 1 °C temperature; 60% ± 10% humidity; and a 12 h/12 h light/dark cycle) with free access to water and a commercial laboratory complete food. Experiments complied with the Guide for the Care and Use of Laboratory Animals as published by the United States of America National Institutes of Health and specifically approved by the Institutional Ethical Committee on Animal Care and Experimentations of Yunnan University of Traditional Chinese Medicine (R-062016003) (Kunming, China). All reasonable efforts were made to minimize animal suffering.

After one week of adaptive feeding, rats were randomized into four groups (*n* = 5 rats per group): normal control (normal saline), model (normal saline), simvastatin \[1.8 mg/(kg•d)\] and *P. kingianum* \[4 g/(kg•d)\] groups. The simvastatin group served as a positive control. The rats were given the treatments intragastrically once a day for 14 consecutive weeks. Simvastatin and *P. kingianum* were prepared separately in normal saline. Dyslipidemia was induced with an HFD (comprised of 1% cholesterol, 10% refined lard, 10% eggs and 79% basic feed) for 14 wk in all groups except for the normal control group.

Sample collection
-----------------

To collect urine samples, rats in each experimental group were housed in metabolic cages for the last three weeks of the 14 wk of treatment. Samples were collected from the metabolic cages and transferred immediately into sterile tubes. After the last administration at week 14, rats were fasted for 12 h and then anesthetized with chloral hydrate. Fasting blood was collected from the hepatic portal vein, and the liver was harvested and stored at -80 °C until use. Blood samples were allowed to clot at 4 °C and centrifuged at 10000 *g* for 10 min, after which serum was collected and stored at -80 °C until assayed.

Measurement of lipid parameters in serum and liver
--------------------------------------------------

TG and TC concentrations were determined using 100 μL of serum and 100 μL of liver homogenate supernatant, in which the protein concentration was measured by BCA assay. All parameters were evaluated on a SpectraMax Plus 384 Microplate Reader (Molecular Devices, Sunnyvale, CA, United States) using commercially available diagnostic kits in accordance with the manufacturer's instructions.

Sample pre-treatment for UHPLC/MS analysis
------------------------------------------

**Serum samples:** Aliquots of serum (200 μL) were diluted with 600 μL of acetonitrile. After vortex-mixing and resting at 4 °C for 20 min, the samples were centrifuged at 12000 rpm and 4 °C for 15 min. The collected supernatants were dried under a gentle nitrogen stream. The obtained residues were re-dissolved in 100 μL of acetonitrile for metabolomics analysis.

**Urine samples:** Samples were lyophilized to a powder using a FD5-3 freeze dryer (SIM International Group Co. Ltd., Newark, DE, United States). The obtained sample powders were dissolved with 100 μL of water and then diluted with 300 μL of acetonitrile. After vortex-mixing and resting at 4 °C for 20 min, the samples were centrifuged at 12000 rpm and 4 °C for 15 min. The collected supernatants were dried with a gentle nitrogen stream. The residues were re-dissolved in 100 μL of acetonitrile for metabolomics analysis.

**Liver samples:** Samples were thawed at room temperature before pre-treatment. Liver tissue (0.2 g) from each rat was homogenized with 1.0 mL of normal saline and then diluted with 300 μL of acetonitrile. After vortex-mixing and resting at 4 °C for 20 min, the samples were centrifuged at 12000 rpm and 4 °C for 15 min. The collected supernatants were dried with a gentle nitrogen stream. The residues were re-dissolved in 100 μL of acetonitrile for metabolomics analysis.

Conditions of UHPLC/MS analysis
-------------------------------

UHPLC/MS analyses were performed on an UHPLC Dionex Ultimate 3000 system coupled with a Thermo Scientific Q-Exactive TM hybrid quadrupole-orbitrap mass spectrometer with a heated-electrospray ionization probe (Thermo Fisher Scientific, San Jose, CA, United States). The UHPLC system consisted of a quaternary pump, an auto-sampler with a temperature control function, a column box, and a photodiode array (PDA) detector.

UHPLC conditions for all samples were: (1) chromatographic column: Thermo C18 column (100 mm × 2.1 mm I.D., 1.9 μm); (2) mobile phase: 0.1% formic acid (A) and acetonitrile (B) with a gradient program (0-3 min, 5% B; 3-5 min, 5% B → 23% B; 5-10 min, 23% B → 43% B; 10-13 min, 43% B → 64% B; 13-16 min, 64% B → 85% B; 16-18 min, 85% B → 100% B; 18-20 min, 100% B → 100% B); (3) flow rate: 0.2 mL/min; and (4) sample injection volume: 4 μL.

MS conditions for all samples were: (1) flow rate: 0.2 mL/min (split from UPLC effluent); (2) detection mode: positive and negative ion; (3) heat block and curved desolvation line temperature: 250 °C; nebulizing nitrogen gas flow: 1.5 L/min; interface voltage: (+) 3.5 kV, (-) -2.8 kV; (4) mass range: MS, m/z 100-1000; MS^2^ and MS^3^, m/z 50-1000; (5) dynamic exclusion time: 10 s; and (6) workstation: Xcalibar 3.0.63 for liquid chromatography combined with data processing, molecular prediction, and precise molecular weight calculations.

Statistical analysis
--------------------

Lipid concentrations in serum and liver are expressed as the mean ± standard deviation (SD). Statistical analyses were performed using SPSS software (13.0 for Windows; SPSS, Chicago, IL, United States). Differences between groups were analyzed by one-way analysis of variance (ANOVA, Dunnett's method). *P* \< 0.05 (two-tailed) was considered statistically significant.

All UHPLC/MS raw files were exported in Xcalibur Raw File (.raw) format and converted to computable document format (.cdf) with Xcalibur 2.0 software (Thermo Fisher Scientific, Waltham, MA, United States). The converted file was then transferred into XCMS online (https://xcmsonline.scripps.edu) to output all data, including groups and comparisons. After that, multivariate statistical analysis, including principal components analysis (PCA) and orthogonal partial least squares discriminant analysis (OPLS-DA), was performed on SIMCA-P 14.1 software (Umetrics, Umeå, Sweden). Potential biomarkers were selected according to the parameters of variable importance in the projection (VIP \> 1.0) from OPLS-DA. The metabolites were identified using METLIN database and compared with data reported previously. Finally, biochemical reactions involving the identified metabolites were found through the Kyoto Encyclopedia of Genes and Genomes (KEGG) in MetaboAnalyst4.0 online (<http://www.metaboanalyst.ca>).

RESULTS
=======

Effects of HFD and P. kingianum on body weight and food intake
--------------------------------------------------------------

In the present study, a HFD rat model was used to investigate the potential effect of *P. kingianum* on HFD-mediated dyslipidemia that was induced by administration of an HFD over a 14-wk period. *P. kingianum* extract was administered by oral gavage at s dosage of 4 g/(kg•d) during HFD administration. During the experiment, none of the rats died, and they had healthy-looking fur, normal drinking habits, moved freely and rapidly responded to external stimuli. As shown in Table [1](#T1){ref-type="table"}, the HFD slightly increased body weight, but *P. kingianum* and simvastatin showed a non-significant effect on body weight and food intake.

###### 

Body weight and food intake of rats

                            **Normal control**   **Model**        **Simvastatin**   ***P. kingianum***
  ------------------------- -------------------- ---------------- ----------------- --------------------
  Initial body weight (g)   200.87 ± 8.83        206.69 ± 8.51    205.03 ± 6.26     206.72 ± 7.82
  Final body weight (g)     494.81 ± 37.43       518.08 ± 40.50   487.62 ± 30.26    480.14 ± 29.91
  Body weight gain (g)      293.94 ± 28.61       311.39 ± 31.98   282.59 ± 24.01    273.42 ± 22.10
  Food intake (g)           15670.81             15042.53         14969.08          14903.86

Values represent the mean ± SD from five animals. *P. kingianum*: *Polygonatum kingianum*.

Effects of P. kingianum on lipids in serum and liver samples from HFD-fed rats
------------------------------------------------------------------------------

The effects of *P. kingianum* on lipids in serum and liver samples were first assessed in a rat model of HFD-induced dyslipidemia. As shown in Table [2](#T2){ref-type="table"}, 14 wk of HFD feeding resulted in a significant increase in TC concentration, but had no significant effect on TG concentration in serum. These effects were significantly reduced by simvastatin, which is known to correct dyslipidemias\[[@B15]\]. Similar to simvastatin, *P. kingianum* remarkably prevented HFD-induced dyslipidemias. Furthermore, Table [3](#T3){ref-type="table"} shows that after 14 wk of HFD feeding, hepatic TC and TG concentrations were significantly increased compared with the normal control group. However, these effects were significantly reduced by *P. kingianum* and simvastatin treatment.

###### 

Effects of *Polygonatum kingianum* on total cholesterol and triglyceride concentrations in rat serum

  **Group**              **TC (mmol/L)**                                                               **TG (mmol/L)**
  ---------------------- ----------------------------------------------------------------------------- ---------------------------------------------
  Normal group           1.42 ± 0.11[c](#T2FN3){ref-type="table-fn"}                                   0.91 ± 0.21
  Model group            1.56 ± 0.11[a](#T2FN1){ref-type="table-fn"}                                   0.97 ± 0.22
  *P. kingianum* group   1.43 ± 0.13[c](#T2FN3){ref-type="table-fn"}                                   0.76 ± 0.13[c](#T2FN3){ref-type="table-fn"}
  Simvastatin group      1.15 ± 0.09[b](#T2FN2){ref-type="table-fn"}[d](#T2FN4){ref-type="table-fn"}   0.77 ± 0.09[c](#T2FN3){ref-type="table-fn"}

Values represent the mean ± SD from five animals.

*P* \< 0.05,

*P* \< 0.01 *vs* the relative normal group.

*P* \< 0.05,

*P* \< 0.01 *vs* the relative model group. *P. kingianum*: *Polygonatum kingianum*; TC: Total cholesterol; TG: Triglyceride.

###### 

Effects of *Polygonatum kingianum* on total cholesterol and triglyceride concentration in rat liver

  **Group**              **TC (mmol/gprot)**                           **TG (mmol/gprot)**
  ---------------------- --------------------------------------------- ---------------------------------------------
  Normal group           0.77 ± 0.19[d](#T3FN3){ref-type="table-fn"}   1.46 ± 0.12[d](#T3FN3){ref-type="table-fn"}
  Model group            1.17 ± 0.22[b](#T3FN1){ref-type="table-fn"}   2.83 ± 0.71[b](#T3FN1){ref-type="table-fn"}
  *P. kingianum* group   0.95 ± 0.15[c](#T3FN2){ref-type="table-fn"}   1.20 ± 0.28[d](#T3FN3){ref-type="table-fn"}
  Simvastatin group      0.94 ± 0.15[c](#T3FN2){ref-type="table-fn"}   1.37 ± 0.43[d](#T3FN3){ref-type="table-fn"}

Values represent the mean ± SD from five animals. ^a^*P* \< 0.05,

*P* \< 0.01 *vs* the relative normal group.

*P* \< 0.05,

*P* \< 0.01 *vs* the relative model group. *P. kingianum*: *Polygonatum kingianum*; TC: Total cholesterol; TG: Triglyceride.

Metabolomic profiling of serum, urine and liver samples
-------------------------------------------------------

Separation conditions of the three samples on the UHPLC column were optimized in terms of peak number, peak shape and reproducibility. Figures [3](#F3){ref-type="fig"}-[](#F4){ref-type="fig"}[5](#F5){ref-type="fig"} shows representative total ion current profiles of the positive and negative ion modes of the four groups in serum, urine and liver, respectively. A large number of molecules were profiled by UHPLC/MS in the analyzed samples. Moreover, there were significant differences in peak number and intensity between the four groups within each of the three sample types. This indicated different metabolomic states in the different groups. Hence, after 14 wk of HFD feeding and administration of *P. kingianum* and simvastatin, the metabolites in serum, urine and liver samples were significantly different.

![Representative total ion current profiles of serum samples in the negative (I) and positive (II) ion modes. A: Control group; B: Model group; and C: *Polygonatum kingianum* group.](WJG-24-5505-g003){#F3}

![Representative total ion current profiles of urine samples in the negative (I) and positive (II) ion modes. A: Control group; B: Model group; and C: *Polygonatum kingianum* group.](WJG-24-5505-g004){#F4}

![Representative total ion current profiles of liver samples in the negative (I) and positive (II) ion modes. A: Control group; B: Model group; and C: *Polygonatum kingianum* group.](WJG-24-5505-g005){#F5}

Multivariate statistical analysis of metabolomic data
-----------------------------------------------------

PCA and OPLS-DA are frequently used for multivariate data analysis because of their ability to cope with highly multivariate, noisy, collinear and possibly incomplete data. PCA is an unsupervised pattern recognition method that is initially used to discern the presence of inherent similarities in profiles. OPLS-DA is a supervised pattern recognition approach based on a partial least squares algorithm that has higher sensitivity for biomarker detection than other methods.

Serum samples
-------------

Figure [6A](#F6){ref-type="fig"} shows the PCA score plots of serum samples in positive and negative ion modes. The normal control, model, simvastatin and *P. kingianum* groups were located in four different regions of the scatter score map. The four sample sets were basically separated. Additionally, the *P. kingianum* group was closer to the normal group than the simvastatin group and partially overlapped with the normal group. This indicated that the composition and concentration of metabolites in the *P. kingianum* group was more similar to the control group. Thus, *P. kingianum* treatment remarkably prevented HFD-induced pathological changes.

![Multivariate statistical analysis of serum samples from model and *Polygonatum kingianum* groups in the negative (I) and positive (II) ion modes. A: Principal components analysis score plots; B: Orthogonal partial least squares discriminant analysis score plots; C: S-plot loading diagram. PK: *Polygonatum kingianum*.](WJG-24-5505-g006){#F6}

OPLS-DA was performed to further verify sample separation from the four groups, to maximize separation between groups and to identify biomarkers from them (Figure [6B](#F6){ref-type="fig"}). The OPLS-DA score plots were described by the cross-validation parameter, R^2^Y, and Q^2^, which represent the total explained variation for the X matrix and the predictability of the model, respectively. In positive and negative ion modes, the four groups were also significantly separated. The *P. kingianum* and simvastatin groups were both close to the control group, which further indicated that *P. kingianum* treatment strongly prevented HFD-induced pathological changes.

To further evaluate the component changes after treatment, an S-Plot loading diagram was established based on OPLS-DA. As shown in Figure [6C](#F6){ref-type="fig"}, each point represents a variable that shows the biomarker that caused the difference between the model and *P. kingianum* groups. The importance of each variable to the classification was evaluated by the VIP value, with molecules with a VIP \> 1.0 selected as potential biomarkers.

Urine samples
-------------

Figure [7A](#F7){ref-type="fig"} shows the PCA score plots of urine samples in positive and negative ion modes. The control group was clearly distinguished from the other three groups, which overlapped partially. In the negative ion mode, there were abnormal sets in the control group, which might be due to individual sample differences that resulted in outlier sample points being outside the 95% confidence interval. The model group was significantly different from the control group. The *P. kingianum* and simvastatin groups had a tendency to deviate from the model group, while the *P. kingianum* group was closer to the cross than the simvastatin group. Compared with the model group, the *P. kingianum* group had a tendency to approach the part samples of the control group and deviate from the part samples of the control group. This was because the appearance of the outlier sample points seriously affected the clustering result. In the positive ion mode, outlier sample points appeared in the control group. The model group had a tendency to deviate to the left compared with the control group. The *P. kingianum* group partially overlapped with the simvastatin group, but did not approach the control group. This was considered to be related to the outlier sample points of the control group.

![Multivariate statistical analysis of urine samples from model and *Polygonatum kingianum* groups in the negative (I) and positive (II) ion modes. A: Principal components analysis score plots; B: Orthogonal partial least squares discriminant analysis score plots; C: S-plot loading diagram. PK: *Polygonatum kingianum*.](WJG-24-5505-g007){#F7}

Figure [7B](#F7){ref-type="fig"} shows the OPLS-DA diagrams of urine samples in positive and negative ion modes. The results suggested that the samples from all groups were perfectly separated, and samples in each group were well clustered. The model group was significantly different from the control group, indicating that physiological metabolism in the urine of rats was seriously interfered with by the HFD. The sample points of the *P. kingianum* group showed a tendency to approach the control group, indicating that HFD-induced changes were relieved after *P. kingianum* administration. Figure [7C](#F7){ref-type="fig"} shows the S-Plot loading diagram of urine samples and the substances with a VIP \> 1.0 that were selected as biomarkers.

Liver samples
-------------

Figure [8A](#F8){ref-type="fig"} displays the PCA score plots of liver samples in positive and negative ion modes. In the negative ion mode, all samples were distributed within the 95% confidence interval. The control group partially overlapped with the model group, which might be due to the unsupervised pattern recognition of PCA analysis. In the positive ion mode, there were outlier sample points in the control group. The *P. kingianum* group was significantly different from the control and model groups, indicating that *P. kingianum* administration interfered with metabolism in the rats.

![Multivariate statistical analysis of liver samples from model and *Polygonatum kingianum* groups in the negative (I) and positive (II) ion modes. A: Principal components analysis score plots; B: Orthogonal partial least squares discriminant analysis score plots; C: S-plot loading diagram. PK: *Polygonatum kingianum*.](WJG-24-5505-g008){#F8}

Figure [8B](#F8){ref-type="fig"} showed the OPLS-DA diagrams of liver samples in positive and negative ion modes. The results suggested that the samples from all groups were perfectly separated, and the samples in each group were well clustered. The *P. kingianum* group was closer to the control group than the simvastatin group, which indicated that *P. kingianum* had significant effects on metabolomic changes in the liver. Figure [8C](#F8){ref-type="fig"} shows the S-Plot loading diagrams of urine samples and the substances with a VIP \> 1.0 that were selected as biomarkers.

Potential biomarker identification
----------------------------------

Nineteen compounds were identified from serum samples, including four in the negative ion mode and 15 in the positive ion mode. They were amino acids, carbohydrates and esters (Table [4](#T4){ref-type="table"}). There were 24 compounds identified from urine samples, including seven in the negative ion mode and 17 in the positive ion mode. They were amino acids, organic acids and esters (Table [5](#T5){ref-type="table"}). Finally, 38 compounds were identified from liver samples, including 18 in the negative ion mode and 22 in the positive ion mode. They were amino acids, organic acids and esters (Table [6](#T6){ref-type="table"}).

###### 

Potential biomarkers identified from serum samples

  **Retention time (min)**   **Molecular weight (Da)**   **VIP**   **Potential biomarker**                  **Formula**          **Change trend**
  -------------------------- --------------------------- --------- ---------------------------------------- -------------------- ------------------
  ESI-                                                                                                                           
  0.928261                   215.032                     6.26699   2-C-Methyl-D-erythritol 4-phosphate      C~5~H~13~O~7~P       down
  8.30572                    245.048                     2.59774   Pimpinellin                              C~13~H~10~O~5~       down
  17.7034                    327.233                     1.53493   3-Methyl-5-pentyl-2-furannonanoic acid   C~19~H~32~O~3~       down
  13.0574                    437.291                     1.03338   4,4\'-Diaponeurosporene                  C~30~H~42~           up
  ESI+                                                                                                                           
  1.11629                    132.102                     21.806    Isoleucine                               C~6~H~13~NO~2~       down
  0.997628                   132.077                     16.0576   3-Guanidinopropanoate                    C~4~H~9~N~3~O~2~     up
  1.0913                     118.087                     14.9589   Aminopentanoic acid                      C5H~11~NO~2~         up
  15.9773                    496.338                     14.2141   LysoPC(16:0)                             C~24~H~50~NO~7~P     up
  2.1554                     166.086                     11.8849   L-Phenylalanine                          C~9~H~11~NO~2~       down
  5.46147                    205.097                     10.6298   L-Tryptophan                             C~11~H~12~N~2~O~2~   up
  0.9767                     203.053                     10.4336   α-D-Glucose                              C~6~H~12~O~6~        down
  18.5687                    400.332                     9.59788   Palmitoyl-L-carnitine                    C~23~H~45~NO~4~      down
  1.09687                    150.058                     9.09347   L-Methionine                             C~5~H~11~NO~2~S      down
  1.10844                    182.081                     8.07313   L-Tyrosine                               C~9~H~11~NO~3~       up
  5.6576                     202.086                     6.72953   2\'-Aminobiphenyl-2,3-diol               C~12~H~11~NO~2~      down
  6.83329                    160.096                     6.65796   4-Hydroxystachydrine                     C~7~H~13~NO~3~       up
  0.960596                   140.068                     6.04106   Pentanoic acid                           C~5~H~11~NO~2~       down
  15.0993                    478.306                     1.00334   1-Oleoyl lysophosphatidic acid           C~21~H~41~O~7~P      down
  10.4394                    288.216                     2.12052   L-Octanoylcarnitine                      C~15~H~29~NO~4~      down

VIP: Variable importance in the projection.

###### 

Potential biomarkers identified from urine samples

  **Retention time (min)**   **Molecular weight (Da)**   **VIP**   **Potential biomarker**                              **Formula**          **Change trend**
  -------------------------- --------------------------- --------- ---------------------------------------------------- -------------------- ------------------
  ESI-                                                                                                                                       
  9.00895                    213.113                     1.42124   2,2\'-(3-Methylcyclohexane-1,1-diyl) diacetic acid   C~11~H~18~O~4~       up
  3.93717                    218.103                     1.32234   Pantothenic acid                                     C~9~H~17~NO~5~       up
  14.0675                    265.148                     1.35019   Cumanin                                              C~15~H~22~O~4~       up
  1.11379                    254.981                     1.3057    Ascorbate-2-sulfate                                  C~6~H~8~O~9~S        down
  0.990052                   308.099                     1.2533    N-Acetylneuraminic acid                              C~11~H~19~NO~9~      down
  3.03597                    365.135                     1.15211   Tetrahydropentoxyline                                C~17~H~22~N~2~O~7~   down
  17.8994                    303.233                     1.12374   Arachidonic acid                                     C~20~H~32~O~2~       up
  ESI+                                                                                                                                       
  8.40988                    173.117                     1.51559   4-Hydroxynonenoic acid                               C~9~H~16~O~3~        up
  6.14752                    172.007                     1.50165   L-Homocysteine sulfonic acid                         C~3~H~9~NO~3~S~2~    up
  10.4959                    187.126                     1.47714   1-Phenyl-5-propyl-1H-pyrazole                        C~12~H~14~N~2~       up
  8.40656                    155.106                     1.46075   4-Oxo-2-nonenal                                      C~9~H~14~O~2~        up
  8.2458                     190.115                     1.44948   N6-Carbamoyl-DL-lysine                               C~7~H~15~N~3~O~3~    up
  1.89902                    213.123                     1.39163   Butethal                                             C~17~H~22~N~2~O~7~   up
  13.7859                    256.263                     1.38483   Palmitic amide                                       C~16~H~33~NO         up
  6.67969                    172.097                     1.34087   (3-Methylcrotonyl)glycine methyl ester               C~8~H~13~NO~3~       up
  17.9836                    315.252                     1.33499   9,10-DiHOME                                          C~18~H~34~O~4~       up
  3.91979                    220.118                     1.30061   Pantothenic acid                                     C~9~H~17~NO~5~       up
  7.08734                    192.066                     1.26102   5-Hydroxyindoleacetic acid                           C~10~H~9~NO~3~       up
  0.839605                   146.165                     1.24838   Spermidine                                           C~7~H~19~N~3~        up
  0.924092                   170.093                     1.24502   1-Methylhistidine                                    C~7~H~11~N~3~O~2~    up
  1.09509                    189.123                     1.23644   N-Alpha-acetyllysine                                 C~8~H~16~N~2~O~3~    up
  9.40433                    139.112                     1.20585   2-Pentylfuran                                        C~9~H~14~O           up
  7.33104                    143.107                     1.20454   2-Octenoic acid                                      C~8~H~14~O~2~        up
  3.91714                    222.122                     1.19506   Vinyl-L-NIO                                          C~9~H~17~N~3~O~2~    up

VIP: Variable importance in the projection.

###### 

Potential biomarkers identified from liver samples

  **Retention time (min)**   **Molecular weight** **(Da)**   **VIP**   **Potential biomarker**   **Formula**          **Change trend**
  -------------------------- ------------------------------- --------- ------------------------- -------------------- ------------------
  ESI-                                                                                                                
  3.95787                    218.103                         9.02621   Pantothenic acid          C~9~H~17~NO~5~       up
  5.52016                    203.082                         5.17533   L-Tryptophan              C~11~H~12~N~2~O~2~   up
  17.9144                    303.232                         2.67441   Arachidonic acid          C~20~H~32~O~2~       up
  8.18557                    241.073                         2.08795   Lumichrome                C~12~H~10~N~4~O~2~   down
  17.6944                    327.233                         2.03102   Docosahexaenoic acid      C~22~H~32~O~2~       down
  9.27129                    201.112                         1.77891   Sebacic acid              C10H18O~4~           down
  18.1942                    279.232                         1.75755   Linoleic acid             C~18~H~32~O2         up
  11.3188                    464.302                         1.75082   Glycocholic acid          C~26~H~43~NO~6~      down
  13.9455                    313.24                          1.66517   9,10-DiHOME               C~18~H~34~O~4~       down
  15.9588                    319.227                         1.58662   16R-HETE                  C~20~H~32~O~3~       up
  7.08734                    353.234                         1.56066   PGE1                      C~20~H~34~O~5~       up
  10.8984                    227.128                         1.45155   Traumatic acid            C~12~H~20~O~4~       down
  2.5168                     251.079                         1.41613   Deoxyinosine              C~10~H~12~N~4~O~4~   down
  11.4285                    221.081                         1.39399   Apiole                    C~12~H~14~O~4~       down
  16.2815                    339.199                         1.28069   Canrenone                 C~22~H~28~O~3~       down
  11.4127                    351.219                         1.14883   PGE2                      C~20~H~32~O~5~       up
  15.6357                    343.228                         1.0584    Medroxyprogesterone       C~22~H~32~O~3~       down
  19.0468                    281.249                         1.03242   Ethyl palmitoleate        C~18~H~34~O~2~       down
  ESI+                                                                                                                
  5.58168                    205.097                         25.6421   L-Tryptophan              C~11~H~12~N~2~O~2~   up
  1.12985                    123.055                         23.4569   Niacinamide               C~6~H~6~N~2~O        up
  3.94534                    220.118                         15.5283   Pantothenic acid          C~9~H~17~NO~5~       down
  1.07398                    244.092                         13.5445   Cytarabine                C~9~H~13~N~3~O~5~    down
  1.65458                    182.081                         12.3842   L-Tyrosine                C~9~H~11~NO~3~       up
  0.901697                   132.077                         8.82297   3-Guanidinopropanoate     C~4~H~9~N~3~O~2~     down
  0.990524                   203.053                         8.06945   L-(+)-Gulose              C~6~H~12~O~6~        down
  2.07851                    269.088                         7.66822   Inosine                   C~10~H~12~N~4~O~5~   down
  15.0942                    302.305                         7.59274   Sphinganine               C~18~H~39~NO~2~      down
  1.48196                    153.04                          7.19394   Xanthine                  C~5~H~4~N~4~O~2~     down
  6.38205                    130.159                         6.90221   Octylamine                C~8~H~19~N           down
  1.21181                    150.058                         6.25979   L-Methionine              C~5~H~11~NO~2~S      down
  0.83538                    146.165                         6.24439   Spermidine                C~7~H~19~N~3~        down
  2.90983                    285.083                         5.64503   Xanthosine                C~10~H~12~N~4~O~6~   down
  1.64612                    165.055                         5.16323   m-Coumaric acid           C~9~H~8~O~3~         down
  11.3366                    181.122                         4.58665   Dihydroactinidiolide      C~11~H~16~O~2~       down
  1.14382                    204.123                         4.29542   Succinylmonocholine       C~9~H~17~NO~4~       down
  2.20661                    218.139                         4.21655   Propionyl-L-carnitine     C~10~H~19~NO~4~      down
  5.73361                    114.092                         3.42289   ε-Caprolactam             C~6~H~11~NO          down
  17.9613                    305.248                         1.8771    Arachidonic acid          C~20~H~32~O~2~       up
  13.2435                    299.201                         1.60893   Norethindrone             C~20~H~26~O~2~       down
  11.7171                    181.122                         1.58994   Dihydroactinidiolide      C~11~H~16~O~2~       down

VIP: Variable importance in the projection.

Metabolic pathway analysis
--------------------------

Pathways with influence values greater than 0.1 were selected as the metabolic pathways\[[@B16]\]. Pathway impact plots were built to visualize the impact of altered metabolic pathways (Figure [9A](#F9){ref-type="fig"}). According to these, the major intervening pathways in serum samples involved phenylalanine, tyrosine, tryptophan, valine, leucine and isoleucine biosynthesis, and phenylalanine, starch, sucrose, glycerophospholipid, tryptophan and tyrosine metabolism (Figure [9A](#F9){ref-type="fig"}, Table [7](#T7){ref-type="table"}). In urine samples, the major intervening pathway involved arachidonic acid metabolism (Figure [9B](#F9){ref-type="fig"}, Table [8](#T8){ref-type="table"}). In liver samples, the major intervening pathways involved phenylalanine, tyrosine and tryptophan biosynthesis, and arachidonic acid, linoleic acid, nicotinate, nicotinamide, sphingolipid, tryptophan and tyrosine metabolism (Figure [9C](#F9){ref-type="fig"}, Table [9](#T9){ref-type="table"}).

###### 

Results of metabolic pathway analysis of serum samples

  **No**.   **Pathway**                                           **Match status**   ***P* value**   **Impact**   **Details**
  --------- ----------------------------------------------------- ------------------ --------------- ------------ -------------
  1         Phenylalanine, tyrosine and tryptophan biosynthesis   2/4                8.19E-04        1.0          KEGG
  2         Phenylalanine metabolism                              2/9                0.0047415       0.40741      KEGG
  3         Valine, leucine and isoleucine biosynthesis           1/11               0.126           0.33333      KEGG
  4         Starch and sucrose metabolism                         1/23               0.24635         0.18783      KEGG
  5         Glycerophospholipid metabolism                        1/30               0.30916         0.19753      KEGG
  6         Tryptophan metabolism                                 1/41               0.39801         0.15684      KEGG
  7         Tyrosine metabolism                                   1/42               0.40552         0.14045      KEGG

KEGG: Kyoto Encyclopedia of Genes and Genomes.

###### 

Results of metabolic pathway analysis in urine samples

  **No**.   **Pathway**                   **Match status**   ***P* value**   **Impact**   **Details**
  --------- ----------------------------- ------------------ --------------- ------------ -------------
  1         Arachidonic acid metabolism   1/36               0.20927         0.32601      KEGG

KEGG: Kyoto Encyclopedia of Genes and Genomes.

###### 

Results of metabolic pathway analysis in liver samples

  **No**.   **Pathway**                                           **Match status**   ***P* value**   **Impact**   **Details**
  --------- ----------------------------------------------------- ------------------ --------------- ------------ -------------
  1         Arachidonic acid metabolism                           3/36               0.042685        0.34677      KEGG
  2         Phenylalanine, tyrosine and tryptophan biosynthesis   1/4                0.085643        0.5          KEGG
  3         Linoleic acid metabolism                              1/5                0.10592         1.0          KEGG
  4         Nicotinate and nicotinamide metabolism                1/13               0.25318         0.2381       KEGG
  5         Sphingolipid metabolism                               1/21               0.37685         0.14286      KEGG
  6         Tryptophan metabolism                                 1/41               0.60553         0.15684      KEGG
  7         Tyrosine metabolism                                   1/42               0.61452         0.14045      KEGG

KEGG: Kyoto Encyclopedia of Genes and Genomes.

![Analysis of metabolic pathways in serum (A), urine (B) and liver (C) samples. a: Phenylalanine, tyrosine and tryptophan biosynthesis; b: Phenylalanine metabolism; c: Valine, leucine and isoleucine biosynthesis; d: Starch and sucrose metabolism; e: Glycerophospholipid metabolism; f: Tryptophan metabolism; g: Tyrosine metabolism; h: Arachidonic acid metabolism; i: Arachidonic acid metabolism; j: Phenylalanine, tyrosine and tryptophan biosynthesis; k: Linoleic acid metabolism; l: Nicotinate and nicotinamide metabolism; m: Sphingolipid metabolism; n: Tryptophan metabolism; and o: Tyrosine metabolism.](WJG-24-5505-g009){#F9}

DISCUSSION
==========

Dyslipidemia is mainly characterized by an increase in TC and TG concentrations in the serum and/or liver. We found that HFD feeding resulted in a significant increase in TC concentration in serum, and in TC and TG concentrations in the liver. This indicated that an HFD could induce hyperlipidemia. *P. kingianum* extract significantly inverted these HFD-induced changes, demonstrating that *P. kingianum* effectively ameliorated dyslipidemia in HFD-fed rats. Additionally, due to fundamental differences in plasma lipoprotein metabolism between rats and humans, it is valuable to use an optimal pathological model to evaluate the lipid-regulating effects of *P. kingianum*.

Metabolomics has been applied widely to the research of drug efficacy and the associated mechanism of action\[[@B17]\]. Currently, the most common samples analyzed in metabolomics are serum, urine, tissues/organs, feces, cells and sub-cells. We used serum, urine and liver samples for metabolomic analysis. The liver is the most important locus for substance metabolism, and also the main site for lipid and amino acid metabolism. External stimuli (*e.g*. a drug) may cause hepatic metabolites to change affecting the physiological function of the liver\[[@B18]\]. Serum reflects the overall status of an organism. When metabolic abnormalities occur in the liver, the metabolites in blood may change through the blood circulation. Urine is an important excretion pathway for metabolites and contains abundant metabolomic information about an organism. Eleven main metabolic pathways affected by *P. kingianum* administration were found in the three samples, including seven in serum and in the liver, and one in urine (Figure [10](#F10){ref-type="fig"}).

![Metabolic pathway map of potential biomarkers. The red and blue font represents potential biomarkers that were up- and down-regulated by *Polygonatum kingianum* treatment, respectively. The blue, black and green box represents amino acid, sugar and lipid metabolism, respectively. A: Phenylalanine, tyrosine and tryptophan biosynthesis, and phenylalanine and tyrosine metabolism; B: Tryptophan metabolism; C: Valine, leucine and isoleucine biosynthesis; D: Starch and sucrose metabolism; E: Glycerophospholipid metabolism; F: Arachidonic acid metabolism; G: Linoleic acid metabolism; H: Nicotinate and nicotinamide metabolism; and I: Sphingolipid metabolism. TCA: Tricarboxylic acid.](WJG-24-5505-g010){#F10}

Phenylalanine, tyrosine and tryptophan biosynthesis and metabolism
------------------------------------------------------------------

Amino acids are the body's raw material for protein synthesis and are catabolic products. They participate in a variety of physiological and pathological processes, and their concentration often reflects the metabolic status of the body. In this study, a number of amino acid metabolic pathways were present in the serum and liver samples, with a decrease in these metabolites, indicating disordered amino acid metabolism. Dyslipidemia causes dysfunctional phenylalanine metabolism by inhibiting conversion of phenylalanine to tyrosine, which increases phenylalanine concentration in the blood. After *P. kingianum* administration, we showed decreased phenylalanine and increased tyrosine content in serum. Tyrosine is synthesized from phenylalanine and is necessary for synthesizing catecholamine hormones such as adrenaline (epinephrine). It also plays an important role in promoting energy metabolism, scavenging free radicals and relieving fatigue\[[@B19]\]. Tyrosine undergoes a series of metabolic reactions to form acetyl-CoA, which participates in the tricarboxylic acid (TCA) cycle. After *P. kingianum* administration, the tyrosine content was increased, which elevated the acetyl-CoA content and further accelerated lipid decomposition through the TCA cycle. Therefore, *P. kingianum* treatment reduced phenylalanine production and further increased tyrosine production by regulating phenylalanine, tyrosine and tryptophan biosynthesis, and phenylalanine and tyrosine metabolism.

Tryptophan, an essential amino acid for humans, has important functions for regulating lipid metabolism\[[@B20]\]. In addition, tryptophan can be converted to acetyl-CoA to participate in the TCA cycle. After *P. kingianum* administration, the tryptophan content was increased, which potentiated acetyl-CoA content and accelerated lipid decomposition. Thus, *P. kingianum* treatment increased tryptophan content and further relieved the disordered lipids by regulating tryptophan metabolism.

Valine, leucine and isoleucine biosynthesis
-------------------------------------------

Biosynthesis of valine, leucine and isoleucine was involved in the serum samples. These amino acids can be broken down into glucose. We found that isoleucine was decreased by *P. kingianum* treatment, indicating a reduction in blood glucose. This affected the oxidation and decarboxylation of pyruvate, and further reduced lipid synthesis with glycerol to alleviate the lipid metabolic disorders.

Starch and sucrose metabolism
-----------------------------

Starch and sucrose metabolism was involved in the serum samples. Glucose is the major energy source and metabolic intermediate of living cells. Starch is a polysaccharide that is composed of several glucose units. Sucrose is a disaccharide comprised of glucose and fructose molecules. Both sucrose and starch can be broken down into glucose by digestive juice. Glucose can be degraded to dihydroxyacetone phosphate by glycolysis. Dihydroxyacetone phosphate can be reduced to glycerol and can also be converted to pyruvate through glycolysis. Pyruvate is converted by oxidation and decarboxylation to acetyl-CoA, which can be used to synthesize fatty acids and further synthesize fat with glycerol\[[@B21]\]. We found that glucose content was reduced after *P. kingianum* administration, which signified that *P. kingianum* reduced lipid synthesis by regulating starch and sucrose metabolism.

Glycerophospholipid metabolism
------------------------------

Glycerophospholipid metabolism was involved in the serum samples. Phosphatidylcholine is the molecule from this pathway that was significantly changed after *P. kingianum* treatment. It is an important component of lipoproteins, a precursor of synthetic cholesterol and it facilitates cholesterol dissolution in bile\[[@B22]\]. Phosphatidylcholine can also disintegrate TGs and cholesterol in blood and in vascular walls, reducing lipid deposition in the vessel walls. It has been reported that people who eat a high-cholesterol diet with added phosphatidylcholine had lower blood cholesterol concentrations, supporting a hypolipidemic effect of phosphatidylcholine\[[@B23]\]. Fat is mainly transported by lipoprotein, while phosphatidylcholine is a vital substance for lipoprotein synthesis. Increased phosphatidylcholine content leads to accelerated hepatic lipoprotein synthesis, which potentiates TG conversion. Thus, insufficient hepatic phosphatidylcholine synthesis is an important contributor to fatty liver. We found that the phosphatidylcholine content was significantly increased after *P. kingianum* treatment, demonstrating that *P. kingianum* regulated glycerophospholipid metabolism to relieve dyslipidemia.

Arachidonic acid metabolism
---------------------------

Arachidonic acid metabolism was involved in the urine and liver samples, and was significantly changed by *P. kingianum* treatment. Cell stimulation results in decomposition of arachidonic acid into a free form by phospholipase A2, with subsequent release into cytosol. The free form produces hundreds of bioactive metabolites by a series of metabolic enzymes. These metabolites have important regulatory effects on lipoprotein metabolism. Arachidonic acid closely relates to development of hyperlipidemia. In addition to effectively reducing blood lipids, it also decreases malondialdehyde. The latter reflects the degree of lipid peroxidation in tissue cells, indicating that arachidonic acid inhibits lipid peroxidation. Our results showed increased arachidonic acid in the urine and liver samples after *P. kingianum* treatment. Thus, *P. kingianum* regulated arachidonic acid metabolism to alleviate dyslipidemia.

Linoleic acid metabolism
------------------------

Linoleic acid metabolism was involved in the liver samples, and linoleic acid was significantly altered with *P. kingianum* treatment. Previous studies found that linoleic acid accelerated fatty acid oxidation and glucose decomposition. Moreover, increased linoleic acid concentrations promoted proliferation and differentiation of fatty cells\[[@B24]\]. We found linoleic acid content to be significantly increased after *P. kingianum* administration, suggesting that *P. kingianum* regulated linoleic acid metabolism.

Niacin and nicotinamide metabolism
----------------------------------

Niacin and nicotinamide metabolism was involved in the liver samples. Nicotinamide was the molecule from this pathway that was significantly altered by *P. kingianum* treatment. Nicotinamide is a metabolite produced by amidation of niacin. Niacin reduces synthesis of low density lipoprotein cholesterol, TC and TG, and increases synthesis of high density lipoprotein cholesterol. This indicates that niacin regulates lipid metabolism\[[@B25]\]. Our results showed that niacinamide content was increased by *P. kingianum* treatment. This suggests that *P. kingianum* increases niacin to alleviate dyslipidemia by regulating hepatic niacin and nicotinamide metabolism.

Sphingolipid metabolism
-----------------------

Sphingolipid metabolism was involved in the liver samples. Sphingolipids regulate important cellular functions, with metabolic abnormalities in these lipids closely related to various diseases. Previous studies found that obese individuals have disordered sphingolipid metabolism, which appears as accumulation of sphingolipids (*e.g*., ceramide) in tissues and blood\[[@B26],[@B27]\]. Sphingolipids can be metabolized to sphingosine. In our study, sphingosine content was decreased after *P. kingianum* treatment, suggesting that *P. kingianum* might decrease sphingolipid content to alleviate dyslipidemia by regulating hepatic sphingolipid metabolism.

Conclusion
----------

Taken together, our data indicated that *P. kingianum* extract alleviated HFD-induced dyslipidemia by regulating a large number of endogenous metabolites in serum, urine and liver. This involved phenylalanine, tyrosine, tryptophan, valine, leucine and isoleucine biosynthesis, and tryptophan, tyrosine, phenylalanine, starch, sucrose, glycerophospholipid, arachidonic acid, linoleic acid, nicotinate, nicotinamide and sphingolipid metabolism. Thus, *P. kingianum* may be a promising lipid regulator to remedy dyslipidemia and further alleviate its related diseases.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Dyslipidemia is an important risk factor for many vicious diseases such as diabetes and cardiovascular disease. Developing dyslipidemia regulators from traditional Chinese medicines (TCMs) to remedy lipid disorders represents attractive strategies for disease therapy. In China, *Polygonatum kingianum* (*P. kingianum*) has been used as an herb and nutritional food for centuries. Known pharmacological activities of *P. kingianum* include immune system stimulation, anti-aging effects and blood glucose regulation.

Research motivation
-------------------

To date, studies on the effects of *P. kingianum* on dyslipidemia and the mechanism for these effects have not been investigated.

Research objectives
-------------------

We aimed to identify the effects and mechanism of action of *P. kingianum* on dyslipidemia using an integrated untargeted metabolomic method.

Research methods
----------------

A rat model of dyslipidemia was induced with a high-fat diet (HFD) and rats were given *P. kingianum* \[4 g/(kg•day)\] intragastrically for 14 wk. Changes in serum and hepatic lipid parameters were evaluated. Metabolites in serum, urine and liver samples were profiled using ultra-high performance liquid chromatography/mass spectrometry followed by multivariate statistical analysis to identify potential biomarkers and metabolic pathways.

Research results
----------------

*P. kingianum* significantly inhibited the HFD-induced increase in total cholesterol and low density lipoprotein cholesterol in serum, and total cholesterol and triglyceride in the liver. *P. kingianum* also reduced hepatic high density lipoprotein cholesterol. *P. kingianum* significantly regulated metabolites in the analyzed samples toward normal status. Nineteen, twenty-four and thirty-eight potential biomarkers were identified in serum, urine and liver samples, respectively. These biomarkers involved 11 main metabolic pathways, including seven in serum and in the liver, and one in urine.

Research conclusions
--------------------

*P. kingianum* alleviated HFD-induced dyslipidemia by regulating many endogenous metabolites in serum, urine and liver samples. This involved phenylalanine, tyrosine, tryptophan, valine, leucine and isoleucine biosynthesis, and tryptophan, tyrosine, phenylalanine, starch, sucrose, glycerophospholipid, arachidonic acid, linoleic acid, nicotinate, nicotinamide and sphingolipid metabolism.

Research perspectives
---------------------

*P. kingianum* may be a promising lipid regulator to treat dyslipidemia and associated diseases.
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